Study summary

The purpose of the trial is to assess the therapeutic effects and the safety profile of IMAB362 combined with EOX (epirubicin, oxaliplatin, capecitabine) as first-line treatment for patients with advanced adenocarcinoma of the stomach, the esophagus or the gastroesophageal junction compared to EOX alone.

Furthermore, sufficient binding of IMAB362 to the target cells is necessary for antitumoral activity. Thus, two dose levels ensuring a serum level above the in vitro predicted clinical efficacy threshold will be investigated.

Additional Study Details

Phase
2
Product
epirubicin
oxaliplatin
capecitabine
zolbetuximab
Type
Interventional
Masking
N/A
Enrollment number
252
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Plain Language Summary
Available Language(s): English

Get more information

Would you like more information about clinical trial sites that are recruiting participants for Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site UKR015
    Poltava, Ukraine
    Completed
    Site GER010
    Dresden, Germany
    Completed
    Site RUS005
    Pyatigorsk, Russian Federation
    Withdrawn
    Site GER019
    Freiburg, Germany
    Withdrawn
    Site GER011
    Lebach, Germany
    Completed
    Site RUS001
    Moscow, Russian Federation
    Completed
    Site BUL002
    Varna, Bulgaria
    Completed
    Site RUS019
    Ryazan, Russian Federation
    Completed
    Site RUS012
    Orel, Russian Federation
    Completed
    Site UKR001
    Donetsk, Ukraine
    Completed
    Site GER013
    Pinneberg, Germany
    Completed
    Site RUS014
    Orenburg, Russian Federation
    Withdrawn
    Site LAT003
    Daugavpils, Latvia
    Completed
    Site RUS013
    Yaroslavl, Russian Federation
    Completed
    Site GER017
    Frankfurt, Germany
    Completed
    Site UKR009
    Zaporizhia, Ukraine
    Completed
    Site BUL004
    Plovdiv, Bulgaria
    Completed
    Site UKR010
    Uzhhorod, Ukraine
    Completed
    Site GER029-01
    Bochum, Germany
    Completed
    Site UKR006
    Lviv, Ukraine
    Completed
    Site LAT002
    Riga, Latvia
    Completed
    Site UKR002
    Donetsk, Ukraine
    Completed
    Site BUL001
    Sofia, Bulgaria
    Completed
    Site GER001
    Essen, Germany
    Completed
    Site BUL003
    Sofia, Bulgaria
    Completed
    Site GER020
    Leipzig, Germany
    Completed
    Site RUS007
    Ivanovo, Russian Federation
    Completed
    Site CZE002
    Olomouc, Czech Republic
    Completed
    Site RUS016
    Bryansk, Russian Federation
    Withdrawn
    Site CZE003
    Prague, Czech Republic
    Withdrawn
    Site RUS004
    Ekaterinburg, Russian Federation
    Completed
    Site UKR007
    Kyiv, Ukraine
    Completed
    Site BUL005
    Sofia, Bulgaria
    Completed
    Site RUS002
    Obninsk, Russian Federation
    Completed
    Site RUS003
    St.Petersburg, Russian Federation
    Completed
    Site RUS017
    Novgorod, Russian Federation
    Completed
    Site GER029
    Bochum, Germany
    Completed
    Site CZE001
    Znojmo, Czech Republic
    Withdrawn
    Site RUS025
    St. Petersburg, Russian Federation
    Completed
    Site RUS006
    Chelyabinsk, Russian Federation
    Completed
    Site GER016
    Münster, Germany
    Completed
    Site GER012
    Bielefeld, Germany
    Completed
    Site UKR005
    Kharkiv, Ukraine
    Completed
    Site RUS010
    St.Petersburg, Russian Federation
    Completed
    Site RUS015
    St.Petersburg, Russian Federation
    Withdrawn
    Site GER018
    Stade, Germany
    Completed
    Site RUS011
    Arkhangelsk, Russian Federation
    Completed
    Site RUS023
    Omsk, Russian Federation
    Completed
    Site RUS009
    Kursk, Russian Federation
    Completed
    Site GER005
    Halle/Saale, Germany
    Completed
    Site UKR004
    Simferopol, Ukraine
    Completed
    Site UKR011
    Sumy, Ukraine
    Completed
    Site LAT001
    Liepaja, Latvia
    Completed
    Site UKR008
    Ivano-Frankivsk, Ukraine
    Completed
    Site UKR003
    Dnipropetrovsk, Ukraine

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?